- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Crystalens patients keep 3-year accommodation
Aliso Viejo, CA—Three years after implantation of the crystalens (eyeonics) accommodating IOL, 92% of patients achieved monocular near-vision acuity of J3 or better measured through the distance correction, according to follow-up results.
Aliso Viejo, CA-Three years after implantation of the crystalens (eyeonics) accommodating IOL, 92% of patients achieved monocular near-vision acuity of J3 or better measured through the distance correction, according to follow-up results.
The results, released recently by eyeonics in accordance with FDA protocol, also show more than 90% of patients are seeing 20/25 or better for bilateral uncorrected distance vision at 1 and 3 years.
All patients showed no loss of accommodation with intermediate vision of J3 or better uncorrected intermediate vision.
"The 3-year data are a reassurance to physicians and their patients that the benefits they enjoy with the crystalens are lasting," said J. Andy Corley, chairman and chief executive officer, eyeonics.
